

Landstingsstyrelsens
beredning för forsknings-
frågor

Anmälan av avsiktsförklaring gällande samarbete med Novartis

Ärendebeskrivning

Anmälan av avsiktsförklaring gällande samarbete mellan Stockholms läns landsting/Karolinska Institutet och Novartis.

Beslutsunderlag

Landstingsdirektörens anmälan den 13 januari 2012
Letter of intent, 2011-05-11

Förslag till beslut

Forskningsberedningen föreslås besluta

att lägga avsiktsförklaringen mellan Stockholms läns landsting/Karolinska Institutet och Novartis till handlingarna.

Förvaltningens synpunkter

Det finns ett nationellt och regionalt intresse av att industrin och sjukvården öppnar sig för varandra. Flera statliga utredningar har påvisat behovet av detta inte minst för att bibehålla och stärka Sveriges ställning i klinisk forskning. Avsiktsförklaringen med Novartis syftar till att utveckla nya former av samarbete. Det överensstämmer med den FoUU-strategi som är beslutad för Stockholms läns landsting. Från landstingets sida kommer detta samarbete att utvidgas till andra aktörer och andra områden och successivt utvärderas.

Toivo Heinsoo
Landstingsdirektör

Thorbjörn Ekström
FOU-direktör



LETTER OF INTENT

May 11, 2011

Dear Harriet Wallberg-Henriksson and Stig Nyman,

Following our meeting at Karolinska Institutet on the 28th of June 2010, at which we identified a number of areas of significant joint interest for future collaboration, this letter of intent – although not legally binding – formulates the parties' intention to enter into joint collaborative efforts within the following areas:

1. **Care & treatment**, to improve accessibility, productivity, patient adherence and outcomes in multiple therapeutic areas, e.g.:
 - a. Develop telehealth solutions for patients with Chronic Obstructive Pulmonary Disease to enhance patient monitoring and outcomes without putting additional strains on physicians' time.
 - b. Create a treatment reminder platform and provide infusion support to primary care for osteoporosis treatment at the Christina Clinic, Sophiahemmet.
2. **Access to innovative value added therapies**, by introducing innovative pricing model solutions for cost driving pharmaceutical drugs and/or therapeutic areas.
3. **Research and development**, through a long term research collaboration containing i.a. the following main components:
 - a. Exchange of knowledge and expertise in various development areas (e.g. drawing upon the KI/KS/SLL biobank repositories in combination with disease related registries) in order to maximize the potential to localize future Novartis clinical trials at KI/KS/SLL.
 - b. Initiating joint research activities/projects in areas of common interest to KI/KS/SLL and Novartis, such as personalized medicine, biomarkers, and existing and future Novartis drug treatments.
 - c. Novartis support for innovation and early research in the form of a yearly scholarship to a young promising scientist at KI/KS/SLL.

- d. An annually recurring Novartis/KI/KS/SLL Joint Research Day with the objective to gather scientists in common areas of interest in order to explore and determine future research project collaborations and other R&D related activities.

The parties have already discussed and identified a number of specific common areas of interest and potential future joint collaboration projects in the research and development field. Novartis is, for an initial time period of three (3) years (possible extension to be evaluated), willing to consider appointing representatives from KI/SLL to two out of a total of five board members of the Novartis Foundation of Medical-Biological Research (the "Foundation"), which currently has assets of approximately 5MSEK, and to consider the possibility to seek funding for collaboration projects from the Foundation.

It is envisioned that this collaboration will be further formalized in the form of legally binding collaboration agreements on a case by case basis as and when a need occurs. Such agreements to typically contain provisions relating to i.a. a governance structure, the allocation of intellectual property rights stemming from the specific collaboration/project and the treatment of intellectual property rights contributed to the collaboration/project, financial commitments, confidentiality, and publication.


We are very enthusiastic in getting this collaboration started and look forward to creating joint solutions and synergies in research and treatment to improve patient outcome.

NOVARTIS PHARMA AG



David Epstein
Division Head Pharma

NOVARTIS SVERIGE AB



Thomas Weigold
Managing Director Scandinavia



Paul David Burns
General Counsel


Acknowledged and accepted:

KAROLINSKA INSTITUTET

Harriet Wallberg-Henriksson
Vice Chancellor of Karolinska Institutet

/ President

STOCKHOLMS LÄNS LANDSTING



Stig Nyman
County Council Commissioner